Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan by Chen Pei, Lin Juei-Jueng, Lu Chin-Song, Ong Cheung-Ter, Hsieh Peiyuan F, Yang Chih-Chao, Tai Chih-Ta, Wu Shey-Lin, Lu Cheng-Hsien, Hsu Yung-Chu, Yu Hsiang-Yu, Ro Long-Sun, Lu Chung-Ta, Chu Chun-Che, Tsai Jing-Jane, Su Yu-Hsiang, Lan Sheng-Hsing, Sung Sheng-Feng, Lin Shu-Yi, Chuang Hui-Ping, Huang Li-Chen, Chen Ying-Ju, Tsai Pei-Joung, Liao Hung-Ting, Lin Yu-Hsuan, Chen Chien-Hsiun, Chung Wen-Hung, Hung Shuen-Iu, Wu Jer-Yuarn, Chang Chi-Feng, Chen Luke, Chen Yuan-Tsong, Shen Chen-Yang, Taiwan SJS Consortium in The New England journal of medicine (2011).

[PMID: 21428768] PubMed

Abstract

Discussed In Paper

Loading...

Variant Annotations

Sign in to see variant annotations.

Dosing Information

Rx Annotation for carbamazepine and HLA-B

Main Findings

Prospective screening for HLA-B*15:02 significantly decreased the incidence of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (p<0.001)

Dosing Protocol

HLA-B*15:02-positive patients who did not take carbamazepine (n=367)HLA-B*15:02-negative patients who received carbamazepine (n=4120)Historical incidence
Number with SJS/TEN0010

Additional Findings

Mild, transient rash and itching developed in 211 subjects - 5 were HLA-B*15:02 positive. More severe cutaneous symptoms developed in 7 subjects - 1 was HLA-B*15:02 positive (urticaria).

Additional Information

  • No. Study Subjects: 4877
  • Ethnicity: Taiwanese